Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $378 to $386.
Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $378 to $386.